| [1］Jennette JC，Falk RJ，Bacon PA，et al.12 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides［J］.Arthritis & Rheumatism，2013，65(1)：1-11. [2］Basu N，McClean A，Harper L，et al.Explaining fatigue in ANCA-associated vasculitis［J］.Rheumatology (Oxford)，2013，52(9)：1680-1685. [3］Gómez-Puerta JA，Gedmintas L，Costenbader KH.The association between silica exposure and development of ANCA-associated vasculitis：systematic review and meta-analysis［J］.Autoimmun Rev，2013，12(12)：1129-1135. [4］de Groot K，Harper L，Jayne DR，et al.EUVAS (European Vasculitis Study Group).Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis：a randomized trial［J］.Ann Intern Med，2009，150(10)：670-680. [5］Harper L，Morgan MD，Walsh M，et al.Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis：long-term follow-up［J］.Ann Rheum Dis，2012，71(6)：955-960. [6］Vanková Z，Ríhová Z，Jancová E，et al.Optimizing the therapeutic strategies in ANCA-associated vasculitis-single centre experience with international randomized trials［J］.Prague Med Rep，2006，107(2)：199-212. [7］Walsh M，Catapano F，Szpirt W，et al.Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis：a meta-analysis［J］.Am J Kidney Dis，2011，57(4)：566-574. [8］Cartin-Ceba R，Golbin JM，Keogh KA，et al.Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s)：ten-year experience at a single center［J］.Arthritis Rheum，2012，64(11)：3770-3778. [9］Jones RB，Tervaert JW，Hauser T，et al.Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis［J］.N Engl J Med，2010，363(3)：211-220. [10］Specks U，Merkel PA，Seo P，et al.Efficacy of remission-induction regimens for ANCA-associated vasculitis［J］.N Engl J Med，2013，369(5)：417-427. [11］Hu W，Liu C，Xie H，et al.Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement［J］.Nephrol Dial Transplant，2008，23(4)：1307-1312. [12］Hiemstra TF，Walsh M，Mahr A，et al.Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis：a randomized controlled trial［J］.JAMA，2010，304(21)：2381-2388. [13］De Groot K，Rasmussen N，Bacon PA，et al.Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis［J］.Arthritis Rheum，2005，52(8)：2461-2469. [14］Metzler C，Miehle N，Manger K，et al.Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis［J］.Rheumatology (Oxford)，2007，46(7)：1087-1091. [15］Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group.Etanercept plus standard therapy for Wegener’s granulomatosis ［J］.N Engl J Med，2005，352(4)：351-361. [16］Martinez V，Cohen P，Pagnoux C，et al.Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies：results of a multicenter，prospective，open-label study of twenty-two patients［J］.Arthritis Rheum，2008，58(1)：308-317. [17］Harper L，Savage CO.ANCA-associated renal vasculitis at the end of the twentieth century-a disease of older patients ［J］.Rheumatology (Oxford)，2005，44(4)：495-501. |
